Nanomerics News
Updates on clinical progress, scientific milestones, awards, and company news.
Media Chain Reaction: Dame Ijeoma Uchegbu Announces Debut Popular Science Book
Nanomerics' CSO Dame Ijeoma Uchegbu announces her debut popular science book, 'Chain Reaction: How Chemistry Shapes Us and Our World', to be published by Hodder & Stoughton on 9 April 2026.
Read more →
Media BBC World Service Outlook: 'One Suitcase, Three Kids — A Broke Scientist Pursues a Dream'
Dame Ijeoma Uchegbu features on BBC World Service's Outlook programme, sharing her personal journey from homeless single mother to nanomedicine pioneer and Dame Commander.
Read more →
Community Nanomerics Continues Support for RSC Broadening Horizons Programme for Fourth Consecutive Year
Nanomerics reaffirms its commitment to diversity and inclusion in the chemical sciences, supporting the RSC Broadening Horizons programme for the fourth consecutive year.
Read more →
Milestone Investiture of Chief Scientific Officer Professor Ijeoma Uchegbu DBE
Nanomerics' Chief Scientific Officer Prof Ijeoma Uchegbu was invested as Dame Commander of the Order of the British Empire at Buckingham Palace, London.
Read more →
Media Dame Ijeoma Uchegbu on BBC Radio 4 Desert Island Discs
Nanomerics' CSO Dame Ijeoma Uchegbu joins Lauren Laverne on Desert Island Discs, sharing the eight records, book and luxury item that define her remarkable journey from scientist to Dame.
Read more →
Clinical SUNLIGHT Trial Meets Primary Endpoints — OC134 Phase I Complete
Nanomerics announces that the OC134 SUNLIGHT Phase I trial has met its primary endpoints. Both OC134 and the MET platform were well tolerated in all healthy volunteers.
Read more →
Clinical Nanomerics Reports Complete Dosing of the Last Volunteer in the OC134 SUNLIGHT Trial
End of dosing confirmed — all volunteers completed the full schedule without moderate or severe adverse events, supporting the safety profile of OC134.
Read more →
Milestone Nanomerics' CSO Named Dame Commander in the UK New Year's Honours 2025
Nanomerics announces that its Chief Scientific Officer, Professor Ijeoma F. Uchegbu, has been appointed Dame Commander of the Order of the British Empire in the New Year's Honours List.
Read more →
Clinical Dosing Has Commenced in the SUNLIGHT Trial (OC134 Phase I)
Following MHRA approval in November 2024, the first volunteer has been dosed in the SUNLIGHT Phase I clinical trial of OC134, the MET-enabled tacrolimus eye drop.
Read more →
Regulatory MHRA Grants Nanomerics Clinical Trial Authorisation for OC134
Nanomerics announces that the UK MHRA has granted a Clinical Trials Authorisation notice for its upcoming OC134 Phase I clinical trial.
Read more →
Media The Life Scientific: Ijeoma Uchegbu on Using Nanoparticles to Transform Medicines
Nanomerics' CSO Ijeoma Uchegbu speaks with Jim Al-Khalili on BBC Radio 4's The Life Scientific about her career, MET platform technology, and the potential of nanoparticles in medicine.
Read more →
Community Nanomerics Hosts RSC Broadening Horizons Industry Site Visit
In collaboration with the Royal Society of Chemistry, Nanomerics hosted an industry site visit for participants of the Broadening Horizons in the Chemical Sciences programme.
Read more →
Community Nanomerics Supports RSC Broadening Horizons Programme for Third Year
Nanomerics proudly announces its third year as an industry partner in the Royal Society of Chemistry's Broadening Horizons in the Chemical Sciences programme.
Read more →
Science Nanomerics CSO Delivers Keynote at Business of Science 2024 Conference
Manchester, UK — Professor Ijeoma Uchegbu delivered the keynote lecture at the Business of Science 2024 Conference, highlighting Nanomerics' MET and METfect platforms.
Read more →
Award Nanomerics Wins the King's Award for Enterprise: Innovation 2024
London, UK — Nanomerics announces it has been awarded the prestigious King's Award for Enterprise in the Innovation category, recognising its Molecular Envelope Technology platform.
Read more →
Science Nanomerics CSO Delivers the 2024 Annual Anne McLaren Lecture
London, UK — Professor Ijeoma Uchegbu delivered the prestigious 2024 Annual Anne McLaren Memorial Lecture, celebrating women in science and innovation.
Read more →
Science Anti-COVID-19 Prophylactic Paper Downloaded Over 3,600 Times
Nanomerics announces that its publication on SARS-CoV-2 inhibition using a mucoadhesive amphiphilic chitosan has been downloaded over 3,600 times since October 2021.
Read more →
Milestone Nanomerics CSO Ijeoma Uchegbu Appointed to Wellcome Board
Nanomerics is proud to announce that its Chief Scientific Officer, Professor Ijeoma Uchegbu, has been appointed to the board of the Wellcome Trust.
Read more →
Science Nanomerics Announces Ocular Progress with New Patents and Key Publications
Nanomerics announces the granting of new patents and publication of key scientific papers supporting the ocular delivery capability of its MET platform technology.
Read more →
Milestone Nanomerics CSO Elected to the Academy of Medical Sciences
The UK Academy of Medical Sciences announced the election of Professor Ijeoma Uchegbu to its influential fellowship of biomedical and health scientists.
Read more → Science Nanomerics Molecular Mask MM019 Inhibits SARS-CoV-2 Replication
Nanomerics announces that its Molecular Mask MM019 has demonstrated inhibition of SARS-CoV-2 replication in ex-vivo human airway epithelial air-liquid interface cultures.
Read more →
Business Double Milestone Payment Strengthens Nanomerics Balance Sheet
Nanomerics announces receipt of its first milestone payments, strengthening the balance sheet and enabling the progression of its clinical programmes.
Read more →
Regulatory Nanomerics Receives pIND Guidance from the US FDA for NM134
Nanomerics received supportive pre-IND guidance from the US FDA on the development of NM134, its MET-enabled tacrolimus formulation for ocular allergic disease.
Read more →